公开(公告)号：US20220267714A1

公开(公告)日：2022-08-25

申请号：US17628834

申请日：2020-07-22

申请人： LUCA SCIENCE INC.

发明人： Yoshihiro OHTA ,  Arima OKUTANI ,  Momoka TAKAHASHI ,  Masashi SUGANUMA ,  Yoshie KAWASE

IPC分类号： C12N1/06 ,  C12N5/071

摘要： The present disclosure relates to methods of obtaining mitochondria from cells, mitochondria obtained by such methods, and uses of mitochondria obtained by such methods.

公开(公告)号：US20220031743A1

公开(公告)日：2022-02-03

申请号：US17275983

申请日：2019-09-13

申请人： LUCA Science Inc.

发明人： Masashi SUGANUMA ,  Hideyoshi HARASHIMA ,  Yuma YAMADA ,  Daisuke SASAKI ,  Takafumi YOKOTA

IPC分类号： A61K35/17 ,  A61K35/15 ,  A61K35/34

摘要： Provided herein are a method for isolation and transplantation of intact mitochondria to a lymphoid organ (a primary lymphoid tissue or a secondary lymphoid tissue), a composition of cells prepared by using a method described herein, and a method for manufacturing cells described herein. In particular, provided herein are methods of isolating intact mitochondria from a donor cell. Also provided herein are methods of transplanting mitochondria into a recipient cell. In some aspects, the methods can be performed in vivo. Further provided are a composition of cells that include the cells prepared using the methods of the present invention.

公开(公告)号：US20200032214A1

公开(公告)日：2020-01-30

申请号：US16349788

申请日：2017-11-16

申请人： LUCA Science Inc.

发明人： Hideyoshi HARASHIMA ,  Yuma YAMADA ,  Jiro ABE ,  Atsuhito TAKEDA

IPC分类号： C12N5/0775 ,  A61K35/34 ,  A61K31/05 ,  A61K9/127 ,  A61P9/04

摘要： An object of the present invention is to provide a novel myocardial stem cell for transplantation which enables maintenance of a therapeutic effect on and/or preventive effect against cardiac failure for a prolonged period, a method for producing the myocardial stem cell, and a cell preparation containing the myocardial stem cell.[Solution]The present invention relates to a method for producing a myocardial stem cell to be used for treatment and/or prevention of cardiac failure, the method comprising the step of introducing a complex of a mitochondria-targeting carrier and a mitochondria activating agent into a myocardial stem cell; a cell produced by the method and a cell preparation containing the cell; and a liposome to be used for producing the cell. According to the present invention, there can be provided a myocardial stem cell which is capable of maintaining a therapeutic effect and/or preventive effect by cell transplantation for a prolonged period.

公开(公告)号：US20230043700A1

公开(公告)日：2023-02-09

申请号：US17789401

申请日：2020-12-25

申请人： LUCA SCIENCE INC.

发明人： Masashi SUGANUMA ,  Yuma YAMADA ,  Hideyoshi HARASHIMA ,  Daisuke SASAKI ,  Mitsue HIBINO ,  Yoshihiro OHTA

IPC分类号： A61K9/127 ,  A61K35/12 ,  C12Q1/6883 ,  A61P43/00

摘要： According to the present invention, there is provided a composition comprising a population of mitochondria with a smaller size and a population of lipid membrane-based vesicles encapsulating mitochondria in a closed space and a method for producing the composition.

公开(公告)号：US20210052629A1

公开(公告)日：2021-02-25

申请号：US16971966

申请日：2019-02-25

申请人： LUCA Science Inc.

发明人： Hideyoshi HARASHIMA ,  Yuma YAMADA ,  Kana SOMIYA ,  Hitoshi OSAKA

IPC分类号： A61K31/7105 ,  A61K31/711 ,  A61K47/69 ,  C12N15/115 ,  C12Q1/6811 ,  C12P19/34

摘要： The present invention relates to a mitochondria-targeted lipid membrane structure encapsulating a nucleic acid represented by any of the following a) to d): a) an RNA comprising, in this order, a nucleotide sequence of a first mitochondrial tRNA, a nucleotide sequence of an mRNA encoding a target protein, and a nucleotide sequence of a second mitochondrial tRNA, wherein the nucleotide sequence of the mRNA has one or more UGAs as a tryptophan codon; b) a DNA comprising a nucleotide sequence of a promoter and a nucleotide sequence complementary to the RNA of a); c) an RNA comprising a nucleotide sequence of an mRNA encoding a target protein, and a nucleotide sequence of a poly(A) chain present at the 3′ end side thereof, wherein the nucleotide sequence of the mRNA has one or more UGAs as a tryptophan codon, AUG as a start codon, and UAA as a stop codon; and d) a DNA comprising a nucleotide sequence of a promoter and a nucleotide sequence complementary to the RNA of c).